Development and validation of UPLC-MS/MS method for in vitro quantitative analysis of pyrazinamide in lipid core-shell nanoarchitectonics for improved metabolic stability

• Autorzy: Thalla Maharshi , Jala Aishwarya , Borkar Roshan M. , Banerjee Subham

Identyfikatory

DOI

10.1556/1326.2021.00916

• Języki publikacji: EN

Abstrakty

EN

Pyrazinamide (PZA), a medication for tuberculosis, has high aqueous solubility and low permeability, undergoes extensive liver metabolism, and exhibits liver toxicity through its metabolites. To avoid this, PZA in lipid core-shell nanoarchitectonics has been formulated to target lymphatic uptake and provide metabolic stability to the incorporated drug. The UPLC-MS/MS method for reliable in vitro quantitative analysis of pyrazinamide (PZA) in lipid core-shell nanoarchitectonics as per ICH guidance was developed and validated using the HILIC column. The developed UPLC-MS/MS method is a simple, precise, accurate, reproducible, and sensitive method for the estimation of PZA in PZA-loaded lipid core-shell nanoarchitectonics for the in vitro determination of % entrapment efficiency, % loading of pyrazinamide, and microsomal stability of lipid core-shell nanoarchitectonics in human liver micro- somes. The % entrapment efficiency was found to be 42.72% (±12.60). Lipid nanoarchitectonics was found to be stable in human liver microsomes, where %QH was found to be 6.20%, that is, low clearance. Thus, this formulation is suitable for preventing PZA-mediated extensive liver metabolism. These findings are relevant for the development of other lipid-mediated, suitable, stable nano- formulations containing PZA through various in vitro methods.

Słowa kluczowe

EN

pyrazinamide; validation; UPLC-MS/MS; HILIC column; in vitro; lipid core-shell nanoarchitectonics

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2022
• Tom: Vol. 34, no. 3
• Strony: 237--245
• Opis fizyczny: Bibliogr. 15 poz., tab., wykr.

Twórcy

autor

Thalla Maharshi

• Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Changsari-781101, Kamrup, Assam, India

autor

Jala Aishwarya

• Department of Pharmaceutical Analysis, NIPER-Guwahati, Changsari-781101, Kamrup, Assam, India

autor

Borkar Roshan M.

• Department of Pharmaceutical Analysis, NIPER-Guwahati, Changsari-781101, Kamrup, Assam, India

• https://orcid.org/0000-0003-1963-7688

autor

Banerjee Subham

• Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Changsari-781101, Kamrup, Assam, India

• https://orcid.org/0000-0002-2984-1159

Bibliografia

• 1. Thalla, M.; Kant, K.; Dalchand; Rawat, R.; Banerjee, S. J. Biomol. Struct. Dyn. 2020, 38, 5195–203.
• 2. Millard, J. D.; Mackay, E. A.; Bonnett, L. J.; Davies, G. R. Syst. Rev. 2019, 8, 329.
• 3. Becker, C.; Dressman, J. B.; Amidon, G. L.; Junginger, H. E.; Kopp,
• S.; Midha, K. K.; Shah, V. P.; Stavchansky, S.; Barends, D. M. J. Pharm. Sci. 2008, 97, 3709–20.
• 4. Tripathi, K. D. Essentials of Medical Pharmacology 6th ed. Jaypee Brothers Med. Publ. P Ltd. 2008, 188.
• 5. Goodman, L. S. Goodman and Gilman’s Manual of Pharmacology and Therapeutics; Mcgraw Hill Professional, 2008.
• 6. Shih, T.-Y.; Pai, C.-Y.; Yang, P.; Chang, W.-L.; Wang, N.-C.; Hu, O. Y.-P. Antimicrob. Agents Chemother. 2013, 57, 1685–90.
• 7. Banerjee, S.; Roy, S.; Nath Bhaumik, K.; Kshetrapal, P.; Pillai, J. Artif. Cells Nanomedicine Biotechnol. 2018, 46, 540–58.
• 8. Pandit, S.; Roy, S.; Pillai, J.; Banerjee, S. ACS Omega. 2020, 5, 4433–48.
• 9. Momin, M. A. M.; Rangnekar, B.; Das, S. C. J. Liq. Chromatogr. Relat. Technol. 2018, 41, 415–21.
• 10. Calleri, E.; De Lorenzi, E.; Furlanetto, S.; Massolini, G.; Caccialanza, G. J. Pharm. Biomed. Anal. 2002, 29, 1089–96.
• 11. Abraham, J. Handbook of transnational economic governance regimes. In Brill | Nijhoff; Tietje, C., Brouder, A., Eds. 2010; pp. 1041–53.
• 12. Banerjee, S.; Chattopadhyay, P.; Ghosh, A.; Kaity, S.; Veer, V. Drug Res. 2013, 63, 450–6.
• 13. Chaudhari, V. S.; Borkar, R. M.; Murty, U. S.; Banerjee, S. J. Pharm. Biomed. Anal. 2020, 186, 113325.
• 14. Thalla, M.; Gangasani, J.; Saha, P.; Ponneganti, S.; Borkar, R. M.; Naidu, V. G. M.; Murty, U. S. N.; Banerjee, S. ASSAY Drug Dev. Technol. 2020, 18, 249–60.
• 15. Niguram, P.; Goswami, A.; Kate, A. S. J. Pharm. Biomed. Anal. 2020, 186, 113279.